|
Decrease of RF titers in adalimumab treated patients: correlation with the clinical response to treatment |
|||||||
| ACR response, week 24 |
Week 0 |
Week 24 |
P |
ACR response, week 48 |
Week 0 |
Week 48 |
P |
|
|
|||||||
| <20% (n = 6) |
130.5 ± 97.9 |
116.5 ± 88.6 |
n.s. |
<20% (n = 3) |
89 ± 73 |
60.3 ± 49.2 |
n.d. |
| ACR 20 (n = 22) |
155.3 ± 147.5 |
109 ± 123 |
<0.0001 |
ACR 20 (n = 23) |
164.5 ± 141.3 |
105.7 ± 112.6 |
<0.0001 |
| ACR 50 (n = 21) |
94.1 ± 60.9 |
57.3 ± 36.2 |
<0.0001 |
ACR 50 (n = 16) |
96.4 ± 73.2 |
51.6 ± 41 |
0.0001 |
| ACR 70 (n = 8) |
94.8 ± 164.2 |
40.4 ± 54 |
n.s. |
ACR 70 (n = 15) |
89.5 ± 123.4 |
37.5 ± 40.7 |
0.018 |
|
Results are means ± SD. ACR, American College of Rheumatology; n.d., not done; n.s., not significant; RF, rheumatoid factor. | |||||||
Atzeni et al. Arthritis Research & Therapy 2006 8:R3 doi:10.1186/ar1851 |
|||||||